Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Eli Lilly & Co.’s experimental weight-loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the drug’s blockbuster potential in the company’s ...

Eli Lilly, facing mounting scrutiny in Congress over big increases in the list price ... Lilly says the price it was paid for popular insulin Humalog fell 8.1% from 2014 to 2018 due to increasing ...

Eli Lilly’s Alzheimer’s drug to face safety, dosing scrutiny from FDA advisers Approval would trigger new competition for Biogen and Eisai’s Leqembi Published: June 7, 2024 at 8:45 a.m. ET ...

Lilly said in a government filing it was cooperating fully with the investigation. That investigation is ongoing. Lilly shares rose 0.37% Monday, to $630.88 each.

Eli Lilly and Co and a former employee agreed to settle a lawsuit in which the ... The New Jersey facility has been under scrutiny by the U.S. Food and Drug Administration since 2019 when ...

Eli Lilly & Co.’s experimental weight-loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the drug’s blockbuster potential in the company’s ...

Eli Lilly & Co.'s experimental weight loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the drug's blockbuster potential in the company's ...